Download the case study and discover the Mediaspace solution
Zejula (niraparib)
The recently FDA approved, ZEJULA™ (Niraparib), is the first and only PARP inhibitor to be approved for the maintenance treatment of women with recurrent ovarian cancer.
The challenges:
Entering medical drug market as a newly FDA approved product
Were not reaching supplementary readers within the target market
Specifi c budget limit with no room for overage
Limited access and information to medical conferences pertaining to ovarian and breast cancer
